Check patentability & draft patents in minutes with Patsnap Eureka AI!

Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction

A technique for urokininogenase and diabetes, which is applied in the application field of preparing medicines for treating and/or preventing diabetes complicated with cerebral infarction, and can solve the problems of increased disability rate and mortality rate, poor prognosis, slow recovery from cerebral infarction and the like

Active Publication Date: 2008-05-21
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Diabetes mellitus with asymptomatic cerebral infarction is also more common, because asymptomatic cerebral infarction generally has no clear signs of nervous system location, only general symptoms such as headache, dizziness, and mental decline, and can only be confirmed by brain CT or MRI. Infarction, or patients with localized signs, head CT or MRI finds infarcts that cannot explain the symptoms and signs, which are easy to be ignored clinically
Therefore, clinically, the treatment of diabetic cerebral infarction is more difficult and the cure rate is lower than that of non-diabetic cerebral infarction.
[0005] Diabetes complicated with cerebral infarction has slow recovery, high recurrence rate, worse prognosis, many sequelae, and significantly higher disability and mortality rates

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction
  • Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction
  • Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Treatment of Human Urinary Kallikrein to Diabetic Patients with Cerebral Infarction

[0013] Experimental objects and grouping: 646 patients with cerebral infarction within 48 hours of onset were randomly selected clinically and divided into treatment group and control group. The treatment group was treated with human urokininogenase, and the control group was given routine treatment with Vibrasol. Among them, there were 532 cases of non-diabetic patients with cerebral infarction (149 cases in the control group and 383 cases in the treatment group), and 114 cases of diabetic patients with cerebral infarction (32 cases in the control group and 82 cases in the treatment group).

[0014] Analysis items: changes in neurological function of patients before and after treatment, using the European Stroke Scale (ESS). The course of treatment is 21 days.

[0015] Efficacy index: the curative effect is judged by the increase rate, and the calculation method is as foll...

Embodiment 2

[0026] Example 2 Effect of human urinary kallikrein on hemorheology in patients with diabetes mellitus complicated with cerebral infarction

[0027] Case selection: 95 cases of diabetic patients with cerebral infarction (44 cases were randomly divided into control group and 51 cases in treatment group), 92 cases of non-diabetic patients with cerebral infarction (42 cases were randomly divided into control group and 50 cases in treatment group). There was no significant difference in age, gender, lesion site and neurological deficit scores between the two groups (P>0.05), which were comparable.

[0028] Experimental method: The control group was given routine treatment with Vibrasol, and the treatment group was given urokininogenase treatment, and the course of treatment was 7 days.

[0029] Experimental indicators: Blood was drawn once before treatment and at the end of treatment in each group, and changes in hemorheology parameters such as whole blood viscosity, plasma viscos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to new medicinal use of human urokininogenase. Human urokininogenase is used in preparing medicine for preventing and treating diabetes combined cerebral infraction. Clinically, the dosage of human urokininogenase in intravenous injection is 1-2 kilounit each time and once or twice a day. Human urokininogenase has obvious curative effect on diabetes combined cerebral infraction.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, the present invention relates to a new medical application of human urinary kallikrein, that is, the application of human urinary kallikrein in the preparation of medicines for treating and / or preventing diabetes complicated with cerebral infarction. Background technique [0002] Human urinary kininogenase is a refined glycoprotein extracted from healthy male urine, with a molecular weight of about 54,000 Daltons. It can expand blood vessels, increase blood flow, improve blood circulation, and increase the deformability and inhibition of red blood cells. Platelet aggregation, prolonging recalcification time and improving blood viscosity. [0003] According to reports, the incidence of diabetic patients with cerebral infarction is 2 to 4 times that of non-diabetic patients, and the incidence rate is significantly increased. According to domestic statistics, the incidence ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/49A61P3/10A61P9/10
Inventor 傅和亮侯永敏苗丕渠吴蓉蓉徐红
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com